Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer

Harter, Philipp; Schrof, I.; Karl, L. M.; Hils, Rita; Kullmann, V; Traut, Alexander; Scheller, Herbert; Bois, Andreas du

doi:10.1055/s-0032-1328602

Cited by 18 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, disinterest in sex was another main reason for inactivity in both our study and the study by Zeng et al The damage to generative organs induced by surgery, chemotherapy, and radiotherapy can decrease the levels of sex hormones, which might result in a decrease in sexual desire. 9 In our study, the median time to the first intercourse experience after surgery among the women who were sexually active was 10 months (range, 6Y60 months) among the women who were sexually active. Some Chinese studies showed that the time until the start of sexual activity after surgery was also a factor that influenced QOL.…”

Section: Discussionmentioning

confidence: 54%

Sexual Function and Quality of Life Among Patients With Endometrial Cancer After Surgery

Gao

Xiao

Bai

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 54%

Sexual Function and Quality of Life Among Patients With Endometrial Cancer After Surgery

Gao

Xiao

Bai

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…There were significant differences between both groups in the SAQ discomfort score (p < .05), but no significant differences in QOL or other scores for sexuality. Even if the quality of sexuality tended to be impaired in GC patients, this did not appear to influence QOL (Harter et al, 2013 and whose cancer was treated with surgery alone (OR = 1.93; 95% CI, 1.22-3.07) were most likely to report positive sexual well-being (Rowlands, Lee, Beesley, & Webb, 2014).…”

Section: Discussionmentioning

confidence: 92%

Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)

et al. 2017

View full text Add to dashboard Cite

The endometrial cancer (EC)-specific Quality of Life module of the European Organization for Research and Treatment of Cancer (EORTC QLQ-EN24), was developed and validated in one study. We independently validated and assessed the psychometric properties of the instrument. Two hundred and eight women with EC before surgery, during adjuvant treatment and follow-up; in three different cancer centres completed the EORTC QLQ-C30 and the EN24. The questionnaire's completion rate was 100%, except sexuality items, that were answered by 35% of patients.All item-scale correlations for the multi-item scales exceeded the .4 criterion and correlated well with their own scale, while correlations with the other scales were low.The internal consistency of all multi-item scales were satisfactory (Cronbach's alpha coefficients ranging from .77 to .97). Discriminance for single-item scales was low. The QLQ-EN24 module discriminated well between clinically different patients, and there were no differences in quality of life questionnaire scales between patients with body mass index ≤30 when compared to those with >30. This validation study supports the reliability, as well as convergent and divergent validity of the EORTC QLQ-EN24. The module is a useful instrument for the assessment of QOL in patients with EC. However, data concerning sexuality should be interpreted with caution. K E Y W O R D Sendometrial cancer, quality of life, questionnaire, validation

show abstract

“…Reasons for not being active include lack of a partner, lack of interest, physical problems, and fatigue. 157,158 Multiple studies have compared the effects of surgery on sexual dysfunction, and results vary, with no conclusive findings. [159][160][161] Studies of radiotherapy also found no consistent effect on sexual function for patients with endometrial cancer.…”

Section: Sexual Healthmentioning

confidence: 99%

Executive Summary of the Uterine Cancer Evidence Review Conference

Chelmow

Brooks

Cavens

et al. 2022

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

receives a stipend as the editor-in-chief of the Medscape Obstetrics and Gynecology Clinical Reference Book, and was on the American Board of Obstetrics and Gynecology Board of Directors during the evidence review and manuscript writing period. David Chelmow is a member of the United States Preventive Services Task Force (USPSTF). This article does not necessarily represent the views and policies of the USPSTF. Rebecca Brooks is a member of an AstraZeneca speakers' bureau related to ovarian cancer, a past advisory board member and consultant for GSK and Merck & Co., Inc., and a past non-branded speaker for Clinical Care Options. Sangini Sheth is a past consultant for Merck & Co., Inc., and a research study grant recipient (drug only: HPV vaccine) from Merck & Co., Inc. She was paid costs of travel and meeting registration (paid directly) and received honoraria payment for an education course from the ASCCP. She also has research grants from the NIH and CDC for studies unrelated to the submitted work.

show abstract

Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer

Cited by 18 publications

References 37 publications

Sexual Function and Quality of Life Among Patients With Endometrial Cancer After Surgery

Sexual Function and Quality of Life Among Patients With Endometrial Cancer After Surgery

Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)

Executive Summary of the Uterine Cancer Evidence Review Conference

Contact Info

Product

Resources

About